论文部分内容阅读
[目的]探讨左旋肉碱联合黄芪注射液治疗急性病毒性心肌炎(AVM )的临床效果及对血清心肌酶标志物水平的影响.[方法]回顾性分析本院收治的104例AVM患者临床资料,根据用药方法的不同将其分为观察组(左旋肉碱联合黄芪注射液)和对照组(左旋肉碱) ,各52例.比较两组患者治疗效果,治疗前后心肌酶水平及不良反应发生情况.[结果]治疗2周后观察组有效率为80 .7%(42／52)高于对照组的59 .6%(31／52) ,差异有统计学意义( P ＜0 .05) .两组治疗后血清CK 、CK‐MB 、CTnT水平均低于治疗前,且观察组低于对照组,差异有统计学意义( P ＜0 .05) .两组患者治疗2周头痛、变应性反应、肝肾功能损伤、呼吸困难等不良反应发生情况比较无统计学意义( P ＞0 .05) .[结论]左旋肉碱联合黄芪注射液治疗AVM临床疗效较佳,可显著降低血清心肌酶标志物水平,且不良反应少,安全性好,值得临床推广应用.“,”To investigate the clinical efficacy of L‐carnitine combined with astragalus injection in the treatment of acute viral myocarditis (AVM ) and explore its effect on serum myocardial enzyme markers .[M ethods]T he clinical data of 104 patients with acute viral myocarditis received admitted our hospital were retrospectively studied .According to the different methods of administration ,they were divided into the obser‐vation group (L‐carnitine combined with Astragalus injection ) and the control group (L‐carnitine treatment only ).T here were 52 cases in each group .T he therapeutic effects of the two groups were compared .Levels of serum myocardial enzyme markers and incidence of adverse reactions before and after treatment were compared as well.[Results]After 2 weeks of treatment ,the total effective rate of the observation group was 80 .7%(42／52) ,w hich was higher than that of the control group 59 .6%(31／52) ,and the difference was statistically sig‐nificant ( P ＜0 .05).T he levels of serum CK ,CK‐MB and CT nT in the two groups after treatment were lower than those before treatment ;the CK ,CK‐MB and CT nT levels of the observation group were lower than those of the control group .T he difference was statistically significant ( P ＜0 .05).T here were no significant differ‐ences in the incidence of adverse reactions such as headache ,allergic reaction ,liver and kidney function dam‐age ,and dyspnea in the two groups ( P ＞0 .05).[Conclusion]L‐carnitine combined with astragalus injection is effective in the treatment of acute viral myocarditis .It can effectively improve cardiac function ,decrease levels of serum myocardial enzyme markers but not increase drug adverse reactions ,w hich is worthy of clinical appli‐cation .